Coxsackievirus B3-Its Potential as an Oncolytic Virus

Related Experiment Video

Updated: Nov 7, 2025

Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

12.9K

Anja Geisler1, Ahmet Hazini2, Lisanne Heimann1

  • 1Department of Applied Biochemistry, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.

Viruses
|April 30, 2021
PubMed

Insights

Coxsackievirus B3 (CVB3) shows promise as an oncolytic virus for cancer treatment. Its ability to target cancer cells and stimulate an immune response offers a new therapeutic avenue.

Area of Science:

  • Oncolytic virotherapy
  • Virology
  • Cancer research

Background:

  • Oncolytic virotherapy is an advanced cancer treatment strategy.
  • Limited patient response necessitates novel oncolytic virus discovery.
  • Coxsackievirus B3 (CVB3) exhibits promising characteristics for oncolysis.

Purpose of the Study:

  • To review the current development status of CVB3 as an oncolytic virus.
  • To outline remaining steps for clinical application of CVB3 in cancer therapy.

Main Methods:

  • Review of existing studies on CVB3 oncolytic potential.
  • Analysis of CVB3's interaction with cancer cells via CAR and heparan sulfate.
  • Evaluation of anti-tumor activity in preclinical models.
  • Assessment of immune response induction.
  • Investigation of CVB3 strain-dependent toxicity and mitigation strategies.

Main Results:

  • CVB3 demonstrates broad anti-tumor activity in mouse models.
  • The virus induces a potent anti-tumor immune response.
  • CVB3 entry receptors (CAR, heparan sulfate) are highly expressed on cancer cells.
  • Toxicity in healthy tissues is strain-dependent and can be reduced via genetic engineering.

Conclusions:

  • CVB3 is a viable candidate for oncolytic virotherapy due to its tumor-targeting and immune-stimulating properties.
  • Further research and development are required to translate CVB3 into a clinically applicable cancer therapeutic.
Keywords:
Coxsackievirus B3cancermiRmicroRNAoncolytic virusvirus adaptation

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.8K
Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

9.6K

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
807
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
5.6K
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
270